Meeting
2021 ASCO Annual Meeting
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.
Authors
Selma Ugurel
Department of Dermatology, University Hospital Erlangen and Department of Dermatology, University of Würzburg, Essen, Germany
Selma Ugurel , Klaus Griewank , Susanne Horn , Rudolf Herbst , Patrick Terheyden , Jochen Utikal , Claudia Pföhler , Jens Ulrich , Alexander Kreuter , Peter Mohr , Ralf Gutzmer , Friedegund Elke Meier , Edgar Dippel , Antje Sucker , Jan-Malte Placke , Eva Hadaschik , Jürgen C. Becker , Michael Weichenthal , Dirk Schadendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9568)
DOI
10.1200/JCO.2021.39.15_suppl.9568
Abstract #
9568
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.
First Author: Chuanliang Cui
Poster
2019 ASCO Annual Meeting
Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
First Author: Sean Matthew McBride
First Author: Ana Oaknin
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).
First Author: Yada Kanjanapan